These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1838041)

  • 1. Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes.
    Dent MT; Veves A; Tebbs SE; Gonzalez AM; Malik RA; Boulton AJ; Ward JD; Wilson RM
    Diabet Med; 1991 Dec; 8(10):911-6. PubMed ID: 1838041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil aldose reductase activity and its association with established diabetic microvascular complications.
    Dent MT; Tebbs SE; Gonzalez AM; Ward JD; Wilson RM
    Diabet Med; 1991 Jun; 8(5):439-42. PubMed ID: 1830528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
    Hamada Y; Kitoh R; Raskin P
    Diabet Med; 1993; 10(1):33-8. PubMed ID: 8435985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocyte Na(+)-K(+)-ATPase activity, metabolic control, and neuropathy in IDDM patients.
    Raccah D; Fabreguetts C; Azulay JP; Vague P
    Diabetes Care; 1996 Jun; 19(6):564-8. PubMed ID: 8725852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
    Boland OM; Blackwell CC; Clarke BF; Ewing DJ
    Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
    Gupta P; Verma N; Bhattacharya S; Mahdi AA; Usman K; Tiwari S; Bhardwaj K
    Can J Diabetes; 2014 Feb; 38(1):22-5. PubMed ID: 24485209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
    Valensi P; Attali JR; Gagant S
    Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function.
    Plater ME; Ford I; Dent MT; Preston FE; Ward JD
    Diabetologia; 1996 Mar; 39(3):336-43. PubMed ID: 8721780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients.
    Ihm SH; Yoo HJ; Park SW; Park CJ
    Metabolism; 1997 Jun; 46(6):634-8. PubMed ID: 9186297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Distal polyneuropathy in children with diabetes mellitus type 1].
    Lotosh NIu; Lineva OA; Volkov IE; Mutalova ZM; Savel'ev SV; Selishcheva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(1):26-30. PubMed ID: 22678671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
    Hamada Y; Hammon K; Raskin P
    J Diabetes Complications; 1992; 6(2):111-5. PubMed ID: 1611134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G; Armstrong FM; Bradbury JE; Chaplin C; Ellis SH; Owens DR; Rosén I; Sönksen P
    J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIH conference. Aldose reductase and complications of diabetes.
    Cogan DG; Kinoshita JH; Kador PF; Robison G; Datilis MB; Cobo LM; Kupfer C
    Ann Intern Med; 1984 Jul; 101(1):82-91. PubMed ID: 6203454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
    Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
    Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of aldose reductase on the oxidative burst in diabetic neutrophils.
    Tebbs SE; Lumbwe CM; Tesfaye S; Gonzalez AM; Wilson RM
    Diabetes Res Clin Pract; 1992 Feb; 15(2):121-9. PubMed ID: 1314160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.